The higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their ... Trius Therapeutics Inc. (NASDAQ: TSRX) is a top small cap name at many Wall Street firms to buy. The continual …
On May 7, 2013, Trius Therapeutics (NasdaqGM: TSRX) reported financial results for the first ... We believe investors should establish a position in the stock at today's price given the attractive long-term value and potential for meaningful ...
the stock has gained $5.37 (13.5%) from a price of $39.68 on January 19, 2012. Impax Laboratories (IPXL) rose 5.7% to close at $25.06, cross its 50-day moving average of $23.76 and 200-day moving average of $21.02. Trius Therapeutics …
Trius Therapeutics Inc. (TSRX) said Monday its antibiotic drug tedizolid phosphate met the primary efficacy endpoint in once daily, 6-day course compared to twice daily, 10-days course of Zyvox or linezolid in patients with acute bacterial …
Most Popular 1.North Korean Chinese Proxy vs US Military Empire Trending Towards Nuclear War! - Nadeem_Walayat 2.Researchers Find $10 Billion Hidden Treasure In A Dead Volcano - OilPrice_Com 3.Gold and Silver : The Battle for …
TSRX) acquired in 2013. Mr. Atwood holds a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University.
Sharing an office as I do with the estimable Bill Patalon, who just scored a huge win with the Cubist Pharmaceuticals Inc (Nasdaq:CBST) takeover of Trius Therapeutics, Inc.(Nasdaq:TSRX), I know this very well. Shares of TSRX are still on a …
SAN DIEGO, May 4, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), announced today that the results of two studies of torezolid phosphate (TR-701) will be presented at the upcoming European Congress of Clinical …
The deal for Trius also boosted that company’s shares by more than 17% in recent action as investors drove the stock to $13.75 for a gain of $2.04, well past Cubist’s purchase price of $13.50. But the deal could be worth another $2 a share …
If there's one sector that's primed for explosive growth right now, it's biotechnology. Its position as a new market leader in the tech sector cannot be overstated. Clearly, investing in biotech is an idea few can afford to ignore. Genentech, the …